Most @entity1 with new-onset @entity302 achieve @entity410 freedom with appropriate @entity734 ( @entity734 ). However, nearly 20 % will continue to have @entity410 despite @entity734 , as either monotherapy or in combination. Despite the growing market of new molecules over the last 20 years, the proportion of @entity302 has not changed. In this review, we report the evidence of efficacy and safety based on phase III randomized controlled clinical trials (RCTs) of @entity734 currently used in the paediatric population. We conducted a literature search using the PubMed database and the Cochrane Database of Systematic Reviews. We also analysed the RCTs of newer @entity734 whose efficacy in adolescents and adults might suggest possible use in @entity1 . Most of the phase III trials on @entity734 in @entity1 have major methodological limitations that considerably limit meaningful conclusions about comparative efficacy between old and new molecules. Since the efficacy of new drugs has only been reported versus placebo, the commonly held opinion that new and newer @entity734 have a better safety profile than old ones does not appear to be supported by evidence. Despite limited solid evidence, pharmacological management has improved over the years as a consequence of increased awareness of some degree of specificity of treatment in relation to @entity302 and attention to adverse events. Future research should be directed taking these factors, as well as the diversity of @entity302 , into consideration.

Antiepileptic Drug Treatment in @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['children'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures'] @entity734 :: ('MESH:D019966', 'Disease') :: ['AEDs', 'antiepileptic drugs'] @entity302 :: ('MESH:D004827', 'Disease') :: ['drug-resistant epilepsies', 'epilepsy', 'different epilepsy syndromes']
@entity302 :: (MESH:D004827,Disease) :: ['Epilepsy']
